PT  - JOURNAL ARTICLE
AU  - RAFAEL LÓPEZ
AU  - CARLOS MÉNDEZ MÉNDEZ
AU  - MÓNICA JORGE FERNÁNDEZ
AU  - CARLOS ROMERO REINOSO
AU  - GUILLERMO QUINTERO ALDANA
AU  - MERCEDES SALGADO FERNÁNDEZ
AU  - JUAN DE LA CÁMARA GÓMEZ
AU  - MARGARITA REBOREDO LÓPEZ
AU  - MANUEL RAMOS VÁZQUEZ
AU  - SONIA CANDAMIO FOLGAR
TI  - Phase II Trial of Erlotinib plus Capecitabine as First-line Treatment for Metastatic Pancreatic Cancer (XELTA Study)
DP  - 2013 Feb 01
TA  - Anticancer Research
PG  - 717--723
VI  - 33
IP  - 2
4099  - http://ar.iiarjournals.org/content/33/2/717.short
4100  - http://ar.iiarjournals.org/content/33/2/717.full
SO  - Anticancer Res2013 Feb 01; 33
AB  - Aim: To evaluate the efficacy and safety of erlotinib plus capecitabine for metastatic pancreatic cancer. Patients and Methods: This was a multicenter, uncontrolled, phase II trial. Patients with untreated metastatic pancreatic cancer received oral capecitabine at 1,000 mg/m2 twice daily on days 1-14, of a 21-day treatment cycle; and oral erlotinib at 150 mg daily. Results: Thirty-two patients were enrolled. The overall response rate (ORR) was 6%, with a median time to treatment failure of 2.1 months. The median follow-up was 7.6 months. The median progression-free survival was 2.1 months and median overall survival was 4.3 months. The one-year survival rate was 22%. Major grade 1 and 2 non-hematological toxicities were skin rash (34%), asthenia (31%) and diarrhea (31%). Grade 3 hematological toxicity was <13%. No grade 4 toxicities were detected. None of the patients died due to treatment toxicity. Conclusion: The combination of capecitabine with erlotinib is an active regimen with a favorable safety profile for patients with metastatic pancreatic cancer.